ALC Stock Recent News

Alcon Inc. (NYSE:ALC ) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants David Saxon - Needham & Company Jeff Johnson - Baird Ryan Zimmerman - BTIG Larry Biegelsen - Wells Fargo Julien Ouaddour - Bank of America Patrick Wood - Morgan Stanley David Adlington - JPMorgan Brett Fishbin - Keybanc Capital Markets Harry Shrives - Citi Tom Stephan - Stifel Issie Kirby - Redburn Atlantic Kavya Deshpande - UBS Jack Reynolds-Clark - RBC Capital Markets Chris Pasquale - Nephron Research LLC Anthony Petrone - Mizuho Group Michael Sarcone - Jefferies Operator Greetings, and welcome to the Alcon Fourth Quarter and 2024 Earnings Call. At this time, all participants are in a listen-only mode.

ALC's performance is driven by robust demand for its innovative products, balanced geographic footprint and strong execution by the team.

Alcon forecast sales of between $10.2 and $10.4 billion for 2025, after the eye care group reported higher fourth-quarter revenue underpinned by its surgical division on Tuesday.

While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

GENEVA--(BUSINESS WIRE)--Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation.

GENEVA--(BUSINESS WIRE)--Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation.

GENEVA--(BUSINESS WIRE)--Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief with Its Longest Lasting Formula Yet.

Evaluate the expected performance of Alcon (ALC) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

GENEVA--(BUSINESS WIRE)--Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension.

ST. CATHARINES, Ontario--(BUSINESS WIRE)-- #yourmarinecarrierofchoice--Algoma Central Corporation (“Algoma” or “the Company”) (TSX: ALC), a leading provider of marine transportation services, today announced that the Company's Board of Directors authorized payment of a quarterly dividend to shareholders of $0.20 per common share. The dividend is payable on March 3, 2025 to shareholders of record on February 14, 2025. This $0.20 common share dividend represents a 5% increase from the $0.19 per share dividend paid on Decembe.